Last reviewed · How we verify
Placebo for vericiguat
This is a placebo control with no active pharmacological mechanism.
This is a placebo control with no active pharmacological mechanism. Used for Control arm in vericiguat clinical trials for heart failure.
At a glance
| Generic name | Placebo for vericiguat |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (vericiguat) through comparison. It contains no active pharmaceutical ingredient and produces no direct therapeutic effect beyond potential placebo response.
Approved indications
- Control arm in vericiguat clinical trials for heart failure
Common side effects
Key clinical trials
- Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) (PHASE2, PHASE3)
- Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome (PHASE2)
- Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction (PHASE2)
- VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway (PHASE2)
- A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (PHASE3)
- SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery (PHASE4)
- The CardioMEMS Vericiguat Heart Failure Trial (PHASE4)
- Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for vericiguat CI brief — competitive landscape report
- Placebo for vericiguat updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI